Group 1 - The innovative drug sector has been actively rising since the end of July, with significant increases in various sub-concept indices [1] - A substantial amount of capital has flowed into the innovative drug field through ETFs, with a total net inflow of 7.551 billion yuan in August [1] - 24 innovative drug ETFs, including QDII, have recorded gains in August, with nearly 80% of them experiencing net inflows [1] Group 2 - The Huatai-PineBridge Hong Kong Innovative Drug ETF saw a net inflow of 2.829 billion yuan in August, leading the sector [1] - The GF CSI Hong Kong Innovative Drug ETF followed closely with a net inflow of 2.711 billion yuan [1] - Other ETFs such as the Hong Kong Innovative Drug ETF, Invesco Great Wall CSI Hong Kong Innovative Drug ETF, and GF Innovative Drug ETF also reported significant net inflows [1]

Group 1 - Tonghua Golden Horse (000766.SZ) released its 2024 annual report on April 18, 2025, with 67 institutional investors holding a total of 90.27 million A-shares, accounting for 9.34% of the total share capital [1] - The top ten institutional investors collectively hold 8.90% of the shares, with a decrease of 2.13 percentage points compared to the previous quarter [1] Group 2 - In the public fund sector, one fund, namely Innovation Drug, increased its holdings by 0.27%, while another fund, Southern CSI 1000 ETF, decreased its holdings by 0.35% [2] - A total of 62 new public funds were disclosed this period, including major funds like Huaxia CSI 1000 ETF and GF Innovation Drug ETF [2] - One foreign institution, Hong Kong Central Clearing Limited, was not disclosed in this period compared to the previous quarter [2]